Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.

Identifieur interne : 001D40 ( Main/Exploration ); précédent : 001D39; suivant : 001D41

Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.

Auteurs : Dharmendra Raghuwanshi [Canada] ; Vivek Mishra ; Dipankar Das ; Kamaljit Kaur ; Mavanur R. Suresh

Source :

RBID : pubmed:22356166

Descripteurs français

English descriptors

Abstract

This work investigates the formulation and in vivo efficacy of dendritic cell (DC) targeted plasmid DNA loaded biotinylated chitosan nanoparticles for nasal immunization against nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) as antigen. The induction of antigen-specific mucosal and systemic immune response at the site of virus entry is a major challenge for vaccine design. Here, we designed a strategy for noninvasive receptor mediated gene delivery to nasal resident DCs. The pDNA loaded biotinylated chitosan nanoparticles were prepared using a complex coacervation process and characterized for size, shape, surface charge, plasmid DNA loading and protection against nuclease digestion. The pDNA loaded biotinylated chitosan nanoparticles were targeted with bifunctional fusion protein (bfFp) vector for achieving DC selective targeting. The bfFp is a recombinant fusion protein consisting of truncated core-streptavidin fused with anti-DEC-205 single chain antibody (scFv). The core-streptavidin arm of fusion protein binds with biotinylated nanoparticles, while anti-DEC-205 scFv imparts targeting specificity to DC DEC-205 receptor. We demonstrate that intranasal administration of bfFp targeted formulations along with anti-CD40 DC maturation stimuli enhanced magnitude of mucosal IgA as well as systemic IgG against N protein. The strategy led to the detection of augmented levels of N protein specific systemic IgG and nasal IgA antibodies. However, following intranasal delivery of naked pDNA no mucosal and systemic immune responses were detected. A parallel comparison of targeted formulations using intramuscular and intranasal routes showed that the intramuscular route is superior for induction of systemic IgG responses compared with the intranasal route. Our results suggest that targeted pDNA delivery through a noninvasive intranasal route can be a strategy for designing low-dose vaccines.

DOI: 10.1021/mp200553x
PubMed: 22356166


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.</title>
<author>
<name sortKey="Raghuwanshi, Dharmendra" sort="Raghuwanshi, Dharmendra" uniqKey="Raghuwanshi D" first="Dharmendra" last="Raghuwanshi">Dharmendra Raghuwanshi</name>
<affiliation wicri:level="1">
<nlm:affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8</wicri:regionArea>
<wicri:noRegion>Alberta T6G 2N8</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mishra, Vivek" sort="Mishra, Vivek" uniqKey="Mishra V" first="Vivek" last="Mishra">Vivek Mishra</name>
</author>
<author>
<name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name>
</author>
<author>
<name sortKey="Kaur, Kamaljit" sort="Kaur, Kamaljit" uniqKey="Kaur K" first="Kamaljit" last="Kaur">Kamaljit Kaur</name>
</author>
<author>
<name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R" last="Suresh">Mavanur R. Suresh</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22356166</idno>
<idno type="pmid">22356166</idno>
<idno type="doi">10.1021/mp200553x</idno>
<idno type="wicri:Area/PubMed/Corpus">001393</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001393</idno>
<idno type="wicri:Area/PubMed/Curation">001393</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001393</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001366</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001366</idno>
<idno type="wicri:Area/Ncbi/Merge">002467</idno>
<idno type="wicri:Area/Ncbi/Curation">002467</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002467</idno>
<idno type="wicri:Area/Main/Merge">001D63</idno>
<idno type="wicri:Area/Main/Curation">001D40</idno>
<idno type="wicri:Area/Main/Exploration">001D40</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.</title>
<author>
<name sortKey="Raghuwanshi, Dharmendra" sort="Raghuwanshi, Dharmendra" uniqKey="Raghuwanshi D" first="Dharmendra" last="Raghuwanshi">Dharmendra Raghuwanshi</name>
<affiliation wicri:level="1">
<nlm:affiliation>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta T6G 2N8</wicri:regionArea>
<wicri:noRegion>Alberta T6G 2N8</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mishra, Vivek" sort="Mishra, Vivek" uniqKey="Mishra V" first="Vivek" last="Mishra">Vivek Mishra</name>
</author>
<author>
<name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name>
</author>
<author>
<name sortKey="Kaur, Kamaljit" sort="Kaur, Kamaljit" uniqKey="Kaur K" first="Kamaljit" last="Kaur">Kamaljit Kaur</name>
</author>
<author>
<name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R" last="Suresh">Mavanur R. Suresh</name>
</author>
</analytic>
<series>
<title level="j">Molecular pharmaceutics</title>
<idno type="eISSN">1543-8392</idno>
<imprint>
<date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Chitosan (chemistry)</term>
<term>Dendritic Cells (metabolism)</term>
<term>Female</term>
<term>Immunity, Humoral (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Nanoparticles (chemistry)</term>
<term>Nucleocapsid Proteins (immunology)</term>
<term>SARS Virus (immunology)</term>
<term>Vaccines, DNA (immunology)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Cellules dendritiques (métabolisme)</term>
<term>Chitosane ()</term>
<term>Femelle</term>
<term>Immunité humorale (immunologie)</term>
<term>Nanoparticules ()</term>
<term>Protéines nucléocapside (immunologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins à ADN (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Chitosan</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en">
<term>Nanoparticles</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Immunité humorale</term>
<term>Protéines nucléocapside</term>
<term>Vaccins antiviraux</term>
<term>Vaccins à ADN</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Immunity, Humoral</term>
<term>Nucleocapsid Proteins</term>
<term>SARS Virus</term>
<term>Vaccines, DNA</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Dendritic Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Cellules dendritiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Female</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Chitosane</term>
<term>Femelle</term>
<term>Nanoparticules</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">This work investigates the formulation and in vivo efficacy of dendritic cell (DC) targeted plasmid DNA loaded biotinylated chitosan nanoparticles for nasal immunization against nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) as antigen. The induction of antigen-specific mucosal and systemic immune response at the site of virus entry is a major challenge for vaccine design. Here, we designed a strategy for noninvasive receptor mediated gene delivery to nasal resident DCs. The pDNA loaded biotinylated chitosan nanoparticles were prepared using a complex coacervation process and characterized for size, shape, surface charge, plasmid DNA loading and protection against nuclease digestion. The pDNA loaded biotinylated chitosan nanoparticles were targeted with bifunctional fusion protein (bfFp) vector for achieving DC selective targeting. The bfFp is a recombinant fusion protein consisting of truncated core-streptavidin fused with anti-DEC-205 single chain antibody (scFv). The core-streptavidin arm of fusion protein binds with biotinylated nanoparticles, while anti-DEC-205 scFv imparts targeting specificity to DC DEC-205 receptor. We demonstrate that intranasal administration of bfFp targeted formulations along with anti-CD40 DC maturation stimuli enhanced magnitude of mucosal IgA as well as systemic IgG against N protein. The strategy led to the detection of augmented levels of N protein specific systemic IgG and nasal IgA antibodies. However, following intranasal delivery of naked pDNA no mucosal and systemic immune responses were detected. A parallel comparison of targeted formulations using intramuscular and intranasal routes showed that the intramuscular route is superior for induction of systemic IgG responses compared with the intranasal route. Our results suggest that targeted pDNA delivery through a noninvasive intranasal route can be a strategy for designing low-dose vaccines.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name>
<name sortKey="Kaur, Kamaljit" sort="Kaur, Kamaljit" uniqKey="Kaur K" first="Kamaljit" last="Kaur">Kamaljit Kaur</name>
<name sortKey="Mishra, Vivek" sort="Mishra, Vivek" uniqKey="Mishra V" first="Vivek" last="Mishra">Vivek Mishra</name>
<name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R" last="Suresh">Mavanur R. Suresh</name>
</noCountry>
<country name="Canada">
<noRegion>
<name sortKey="Raghuwanshi, Dharmendra" sort="Raghuwanshi, Dharmendra" uniqKey="Raghuwanshi D" first="Dharmendra" last="Raghuwanshi">Dharmendra Raghuwanshi</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D40 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D40 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22356166
   |texte=   Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22356166" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021